Patents by Inventor Andrew John Bessire

Andrew John Bessire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METABOLITES OF GLP1R AGONISTS
    Publication number: 20240391908
    Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
    Type: Application
    Filed: July 31, 2024
    Publication date: November 28, 2024
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar, Timothy Frank Ryder
  • Metabolites of GLP1R agonists
    Patent number: 12065434
    Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: August 20, 2024
    Assignee: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar, Timothy Frank Ryder
  • METABOLITES OF GLP1R AGONISTS
    Publication number: 20220213072
    Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
    Type: Application
    Filed: December 9, 2021
    Publication date: July 7, 2022
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar, Timothy Frank Ryder
  • METABOLITES OF GLP1R AGONISTS
    Publication number: 20220193063
    Abstract: The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar